Positive results were also described in the clinical trial of secukinumab and ixekizumab in various IL-17- related immune mediated disease, such as Rheumatoid Arthritis (RA), ankylosing spondylitis, and non-infectious uveitis (112–114). Here, IL17A is linked to rheumatoid arthritis.